PF-562271 HCl: Precision FAK/Pyk2 Inhibitor for Tumor Growth Studies

Principle Overview: Leveraging PF-562271 HCl in Cancer Research

PF-562271 HCl, available from APExBIO, is a potent, ATP-competitive, and reversible FAK/Pyk2 inhibitor engineered for high selectivity. With an IC₅₀ of 1.5 nM for FAK and 14 nM for Pyk2, and over 100-fold selectivity versus most other kinases, it enables researchers to dissect the focal adhesion kinase signaling pathway with minimal off-target effects (product information). This makes PF-562271 HCl a pivotal tool for studies of tumor growth inhibition, metastatic progression, and microenvironment modulation.

FAK and Pyk2 orchestrate cell adhesion, migration, proliferation, and survival—central processes in cancer biology. By inhibiting these kinases, PF-562271 HCl provides mechanistic insight into how tumors grow, invade, and resist conventional therapies. The compound’s robust performance in both in vitro and in vivo models underscores its value for translational oncology as demonstrated in recent literature (article on advanced FAK/Pyk2 inhibitor science).

Step-by-Step Workflow: Protocol Enhancements for Reproducible Assays

Successful integration of PF-562271 HCl into cancer research workflows hinges on optimized preparation, dosing, and readout strategies. The following protocol enhancements are distilled from current best practices and literature-backed recommendations:

Protocol Parameters

• Stock solution preparation: Dissolve PF-562271 HCl at ≥26.35 mg/mL in DMSO with gentle warming (37°C); avoid water or ethanol due to insolubility (product information).
• Cellular assay dosing: Apply at final concentrations ranging from 10 nM to 1 μM for 24–72 hours, titrating to determine optimal FAK phosphorylation inhibition based on cell type (comparative guideline).
• Animal model administration: Deliver via intraperitoneal injection at 25–50 mg/kg daily, monitoring tumor growth and metastatic spread over 2–4 weeks as supported in xenograft studies.

Ensure solutions are freshly prepared or stored at -20°C to maintain stability. Regularly validate compound potency by assessing FAK phosphorylation at Tyr397 via Western blot or ELISA.

Key Innovation from the Reference Study

The study by Keller et al. (2023) illuminates a critical axis in therapy-resistant HER2-positive breast cancer: the link between choline metabolism (via EDI3) and tumor viability/growth. By demonstrating that targeting downstream kinases and metabolic regulators decreases tumor cell viability, the work directly supports the rationale for using precise kinase inhibitors like PF-562271 HCl in models of acquired therapy resistance. This insight translates into practical assay design by prioritizing dual-pathway inhibition—combining FAK/Pyk2 blockade with metabolic interventions—to study synergistic or adaptive responses. For example, researchers can use PF-562271 HCl alongside EDI3 silencing or pharmacological inhibitors to probe combinatorial effects on cell survival and metastatic potential.

Advanced Applications and Comparative Advantages

PF-562271 HCl has emerged as the benchmark for studying the focal adhesion kinase signaling pathway in both basic and preclinical research settings. Its nanomolar potency and selectivity ensure precise pathway modulation, while reversibility allows for the study of both acute and chronic inhibition scenarios.

Compared to broader-spectrum tyrosine kinase inhibitors, PF-562271 HCl minimizes confounding off-target effects, leading to cleaner phenotypic readouts. This is particularly important in complex systems such as 3D tumor spheroids, organotypic cultures, and in vivo xenograft models where pathway-specific effects must be distinguished from global cytotoxicity. Notably, the scenario-driven best practices article highlights how PF-562271 HCl enhances reproducibility in cell viability, proliferation, and cytotoxicity assays—enabling robust comparison across experiments and laboratories.

Furthermore, recent work (molecular intricacies review) shows that PF-562271 HCl is indispensable for dissecting metastatic signaling cascades, providing a foundation for next-generation therapeutic strategies that seek to target the tumor microenvironment.

Troubleshooting and Optimization Tips

• Compound solubility: If PF-562271 HCl does not fully dissolve in DMSO, gently warm the solution and vortex thoroughly; do not use water or ethanol, as per product guidelines.
• DMSO toxicity: Keep final DMSO concentration in cell culture below 0.1% (v/v) to avoid confounding cytotoxic effects.
• Variable response in cell lines: Screen multiple concentrations (10, 50, 100, 500 nM) to determine the optimal dose for your specific cellular model; certain lines may exhibit differential sensitivity linked to FAK expression levels or mutation status.
• Phosphorylation readouts: Use validated anti-pFAK (Tyr397) antibodies and include appropriate positive/negative controls in Western blot or ELISA.
• Long-term storage: Aliquot stock solutions to prevent repeated freeze-thaw cycles, which can degrade compound potency.

Future Outlook: Integrating FAK/Pyk2 Inhibition into Precision Oncology

As highlighted in the reference study, resistance to targeted therapies in breast cancer underscores the urgent need for innovative combinatorial strategies. PF-562271 HCl’s ability to precisely modulate focal adhesion kinase activity positions it at the forefront of efforts to overcome therapy resistance and unravel the interplay between adhesion signaling and cancer metabolism. Next steps include integrating PF-562271 HCl with metabolic inhibitors (such as those targeting EDI3) and immune modulators to probe synthetic lethal interactions and optimize treatment regimens.

Moreover, as outlined in recent reviews, a key direction will be leveraging PF-562271 HCl in biomarker-driven studies to stratify patient-derived models and guide clinical translation. The compound’s established profile in both xenograft and transgenic mouse models provides a robust platform for preclinical validation of emerging therapeutic hypotheses.

Conclusion

PF-562271 HCl, sourced reliably from APExBIO, remains the gold-standard FAK/Pyk2 inhibitor for mechanistic and translational cancer research. Its optimized protocol parameters, high selectivity, and proven efficacy in tumor growth and metastasis inhibition make it an indispensable tool for advancing the precision oncology frontier. For detailed product specifications and ordering, visit the PF-562271 HCl product page.